← Leaderboards
M Guillaume Wientjes
Ohio State University
$5,257,664
Attributed
$8,347,481
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–17$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$8,347,481 · 7
By mechanism
R01$7,997,690 · 6
R21$349,791 · 1
Top collaborators
- Jessie L.-S. Au19 shared
Most similar at Ohio State University
Same institution · by research overlap
- Jessie L.-S. Au$10,705,345
- David P Carbone$20,647,321
- Mark J. Mitton-Fry$2,212,675
- Miguel Angel Villalona$9,621,601
- Yasuko Rikihisa$20,217,328
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseIn VivoTumorIn VitroPaclitaxelProteinsSolid NeoplasmChemotherapyPharmacodynamicsPharmaceutical PreparationsMolecularCellsMalignant NeoplasmsCombined Modality TherapyDrug KineticsRna InterferenceUncertaintyToxic EffectComputer SimulationTreatment ProtocolsLiteratureBaseResponseProperty
Grant awards (31)
Targeting multiple signaling steps to achieve synergy$390,100
R01 · FY2017 · CA · contact PI
Targeting multiple signaling steps to achieve synergy$390,100
R01 · FY2016 · CA · contact PI
Targeting multiple signaling steps to achieve synergy$378,396
R01 · FY2015 · CA · contact PI
Synergistic chemo-siRNA combination therapy$372,483
R01 · FY2015 · CA · contact PI
Synergistic chemo-siRNA combination therapy$361,309
R01 · FY2014 · CA · contact PI
Multiscale computational models for developing combination cancer therapy$337,479
R01 · FY2014 · GM
Capturing dynamic and inter-dependent biointerfaces in nanotechnology designs$302,686
R01 · FY2014 · EB
Targeting multiple signaling steps to achieve synergy$1
R01 · FY2014 · CA · contact PI
Targeting multiple signaling steps to achieve synergy$366,694
R01 · FY2013 · CA · contact PI
Synergistic chemo-siRNA combination therapy$350,134
R01 · FY2013 · CA · contact PI
Multiscale computational models for developing combination cancer therapy$325,667
R01 · FY2013 · GM
Capturing dynamic and inter-dependent biointerfaces in nanotechnology designs$294,261
R01 · FY2013 · EB
Targeting multiple signaling steps to achieve synergy$390,100
R01 · FY2012 · CA · contact PI
Synergistic chemo-siRNA combination therapy$372,483
R01 · FY2012 · CA · contact PI
Multiscale computational models for developing combination cancer therapy$337,479
R01 · FY2012 · GM
Capturing dynamic and inter-dependent biointerfaces in nanotechnology designs$297,956
R01 · FY2012 · EB
Synergistic chemo-siRNA combination therapy$372,483
R01 · FY2011 · CA · contact PI
Multiscale computational models for developing combination cancer therapy$286,700
R01 · FY2011 · GM
Capturing dynamic and inter-dependent biointerfaces in nanotechnology designs$253,124
R01 · FY2011 · EB
Enhanced Chemosensitivity of Pancreatic Cancer$258,035
R01 · FY2008 · CA · contact PI
Enhanced Chemosensitivity of Pancreatic Cancer$258,035
R01 · FY2007 · CA · contact PI
Enhanced Chemosensitivity of Pancreatic Cancer$265,742
R01 · FY2006 · CA · contact PI
Tumor priming to promote nanoparticle gene delivery$156,936
R21 · FY2006 · CA · contact PI
Enhanced Chemosensitivity of Pancreatic Cancer$272,138
R01 · FY2005 · CA
Tumor priming to promote nanoparticle gene delivery$192,855
R21 · FY2005 · CA
Enhanced Chemosensitivity of Pancreatic Cancer$272,138
R01 · FY2004 · CA
INTRAPROSTATIC DOXORUBICIN THERAPY$7,612
R01 · FY2002 · CA
INTRAPROSTATIC DOXORUBICIN THERAPY$104,335
R01 · FY2001 · CA
INTRAPROSTATIC DOXORUBICIN THERAPY$312,776
R01 · FY2000 · CA
INTRAPROSTATIC DOXORUBICIN THERAPY$37,004
R01 · FY2000 · CA
INTRAPROSTATIC DOXORUBICIN THERAPY$30,240
R01 · FY2000 · CA